FDA Drugs (New Approvals & NDA)Original article
Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
RegulatoryTyenneNegative
AI Analysis
Summary
Fresenius Kabi issued a nationwide recall of one lot of Tyenne (tocilizumab-aazg) Injection 400 mg/20 mL vials following an internal investigation that found the presence of glass particles in the product.
Outcome Details
Nationwide recall of one lot of Tyenne 400 mg/20 mL vials due to presence of glass particles
Importance:6/10
Sentiment:
-0.85
product recallquality issuemanufacturingsafety
Read the original article
Published by FDA Drugs (New Approvals & NDA) on August 11, 2026 2:30 PM